Nucleotide prodrugs of 2′-deoxy-2′-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase

Journal of Medicinal Chemistry

Volumn 57, Issue 5, 2014, Pages 1836-1844

  Jonckers, Tim H M ^a   Vandyck, Koen ^a   Vandekerckhove, Leen ^a,c   Hu, Lili ^a   Tahri, Abdellah ^a   Van Hoof, Steven ^a,d   Lin, Tse I ^a,e   Vijgen, Leen ^a   Berke, Jan Martin ^a   Lachau Durand, Sophie ^a   Stoops, Bart ^a   Leclercq, Laurent ^a   Fanning, Gregory ^a   Samuelsson, Bertil ^b   Nilsson, Magnus ^b,f   Rosenquist, Åsa ^b   Simmen, Kenny ^a   Raboisson, Pierre ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b MEDIVIR AB   (Sweden)

^c Vlaamse Milieumaatschappij   (Belgium)

^d HASSELT UNIVERSITY   (Belgium)

^e Roche China Ltd   (China)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' SPIROOXETANE RIBONUCLEOSIDE; BENZYL 2[[[ 5 [2,4 DIOXO 3,4 DIHYDROPYRIMIDIN 1(2H) YL 8 HYDROXY 1,6 DIOXA SPIRO[3.4]OCTAN 7 YL] METHOXY](NAPHTHALEN 1 YLOXY)PHOSPHORYL]AMINO]PROPANOATE; BENZYL 2[[[ 5 [2,4 DIOXO 3,4 DIHYDROPYRIMIDIN 1(2H) YL 8 HYDROXY 1,6 DIOXA SPIRO[3.4]OCTAN 7 YL] METHOXY](PHENOXY)PHOSPHORYL]AMINO]BUTANOATE; BENZYL 2[[[ 5 [2,4 DIOXO 3,4 DIHYDROPYRIMIDIN 1(2H) YL 8 HYDROXY 1,6 DIOXA SPIRO[3.4]OCTAN 7 YL] METHOXY](PHENOXY)PHOSPHORYL]AMINO]PROPANOATE; BUTYL 2[[[ 5 [2,4 DIOXO 3,4 DIHYDROPYRIMIDIN 1(2H) YL 8 HYDROXY 1,6 DIOXA SPIRO[3.4]OCTAN 7 YL] METHOXY](PHENOXY)PHOSPHORYL]AMINO]PROPANOATE; PHOSPHORAMIDIC ACID DERIVATIVE; RIBONUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PENETRATION; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CULTURE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; NONHUMAN; RAT; REPLICON; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HEPACIVIRUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; RIBONUCLEOSIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84896304978     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4015422     Document Type: Article

References (36)

1. Prusoff, W. H. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine Biochim. Biophys. Acta 1959, 32, 295-296
2. Ghobrial, R. M.; Steadman, R.; Gornbein, J.; Lassman, C.; Holt, C. D.; Chen, P.; Farmer, D. G.; Yersiz, H.; Danino, N.; Collisson, E.; Baquarizo, A.; Han, S. S.; Saab, S.; Goldstein, L. I.; Donovan, J. A.; Esrason, K.; Busuttil, R. W. A 10-year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients Ann. Surg. 2001, 234, 384-393
3. Simmonds, P. Genetic diversity and evolution of hepatitis C virus-15 years on J. Gen. Virol. 2004, 85, 3173-3188
4. McHutchison, J. G.; Manns, M. P.; Muir, A. J.; Terrault, N. A.; Jacobson, I. M.; Afdhal, N. H.; Heathcote, E. J.; Zeuzem, S.; Reesink, H. W.; Garg, J.; Bsharat, M.; George, S.; Kauffman, R. S.; Adda, N.; Di Bisceglie, A. M. Telaprevir for previously treated chronic HCV infection N. Engl. J. Med. 2010, 362, 1292-1303
5. Revill, P.; Serradell, N.; Bolos, J.; Rosa, E. Telaprevir Drugs Future 2007, 32, 788
6. Jensen, D. M. A new era of hepatitis C therapy begins N. Engl. J. Med. 2011, 364, 1272-1274
7. Lindenbach, B. D.; Rice, C. M. Unravelling hepatitis C virus replication from genome to function Nature 2005, 436, 933-938
8. Behrens, S.-E.; Tomei, L.; De Francesco, R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus EMBO J. 1996, 15, 12-22
9. Lohmann, V.; Korner, F.; Herian, U.; Bartenschlager, R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity J. Virol. 1997, 71, 8416-8428
10. Lesburg, C. A.; Cable, M. B.; Ferrari, E.; Hong, Z.; Mannarino, A. F.; Weber, P. C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site Nat. Struct. Biol. 1999, 6, 937-943
11. Legrand-Abravanel, F.; Nicot, F.; Izopet, J. New NS5B polymerase inhibitors for hepatitis C Expert Opin. Invest. Drugs 2010, 19, 963-975
12. Sarrazin, C.; Zeuzem, S. Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 2010, 138, 447-462
13. McCown, M. F.; Rajyaguru, S.; Le Pogam, S.; Ali, S.; Jiang, W.-R.; Kang, H.; Symons, J.; Cammack, N.; Najera, I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to non-nucleoside polymerase or protease inhibitors Antimicrob. Agents Chemother. 2008, 52, 1604-1612
14. Kim, J.; Chong, Y. Understanding the RNA-specificity of HCV RdRp: Implications for anti-HCV drug discovery Bull. Korean Chem. Soc. 2006, 27, 59-64
15. Tan, S.-L. Hepatitis C Viruses: Genomes and Molecular Biology; Horizon Bioscience: Wymondham, UK, 2006.
16. Bressanelli, S.; Tomei, L.; Rey, F. A.; De Francesco, R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides J. Virol. 2002, 76, 3482-3492
17. Klumpp, K.; Kalayanov, G.; Ma, H.; Le Pogam, S.; Leveque, V.; Jiang, W.-R.; Inocencio, N.; De Witte, A.; Rajyaguru, S.; Tai, E.; Chanda, S.; Irwin, M. R.; Sund, C.; Winqist, A.; Maltseva, T.; Eriksson, S.; Usova, E.; Smith, M.; Alker, A.; Najera, I.; Cammack, N.; Martin, J. A.; Johansson, N. G.; Smith, D. B. 2′-Deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha- hydroxylgroups J. Biol. Chem. 2008, 283, 2167-2175
18. Gunic, E.; Girardet, J.-L.; Ramasamy, K.; Stoisavljevic-Petkov, V.; Chow, S.; Yeh, L.-T.; Hamatake, R. K.; Raney, A.; Hong, Z. Cyclic monophosphate prodrugs of base-modified 2′-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication Bioorg. Med. Chem. Lett. 2007, 2452-2455
19. Olsen, D. B.; Eldrup, A. B.; Bartholomew, L.; Bhat, B.; Bosserman, M. R.; Ceccacci, A.; Colwell, L. F.; Fay, J. F.; Flores, O. A.; Getty, K. L.; Grobler, J. A.; LaFemina, R. L.; Markel, E. J.; Migliaccio, G.; Prhavc, M.; Stahlhut, M. W.; Tomassini, J. E.; MacCoss, M.; Hazuda, D. J.; Carroll, S. S. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties Antimicrob. Agents Chemother. 2004, 48, 3944-3953
20. Jonckers, T. H. M.; Lin, T.; Buyck, C.; Lachau-Durand, S.; Vandyck, K.; Van Hoof, S.; Vandekerckhove, L. A. M.; Hu, L.; Berke, J. M.; Vijgen, L.; Dillen, L. L. A.; Cummings, M. D.; de Kock, H.; Nilsson, M.; Sund, C.; Rydegard, C.; Samuelsson, B.; Rosenquist, A.; Fanning, G.; Van Emelen, K.; Simmen, K.; Raboisson, P. 2′-Deoxy-2′-spirocyclopropylcytidine revisited: A new and selective inhibitor of the hepatitis C virus NS5B polymerase J. Med. Chem. 2010, 53, 8150-8160
21. Pierra, C.; Benzaria, S.; Amador, A.; Moussa, A.; Mathieu, S.; Storer, R.; Gosselin, G. NM 283, an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine Nucleosides, Nucleotides Nucleic Acids 2005, 24, 767-770
22. Murakami, E.; Niu, C.; Bao, H.; Micolochick Steuer, H. M.; Whitaker, T.; Nachman, T.; Sofia, M. A.; Wang, P.; Otto, M. J.; Furman, P. A. The mechanism of action of β- d -2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to β- d -2′-deoxy- 2′-fluoro-2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase Antimicrob. Agents Chemother. 2008, 52, 458-464
23. Burkhard, J. A.; Wuitschik, G.; Rogers-Evans, M.; Muller, K.; Carreira, E. M. Oxetanes as versatile elements in drug discovery and synthesis Angew. Chem., Int. Ed. 2010, 49, 9052-9067
24. Babu, B. R.; Keinicke, L.; Petersen, M.; Nielsen, C.; Wengel, J. 2′-Spiro ribo- and arabinonu-cleosides: Synthesis, molecular modelling and incorporation into oligodeoxynucleotides Org. Biomol. Chem. 2003, 1, 3514-3526
25. Du, J.; Chun, B.-K.; Mosley, R.; Bansal, S.; Bao, H.; Lam, A.; Espiritu, C.; Murakami, E.; Niu, C.; Micolochick, S.; Furman, P.; Sofia, M. Use of 2′-spirocyclic ethers in HCV nucleoside design. J. Med. Chem. [Online early access]. DOI: 10.1021/jm401224y. Published Online: Sept 30, 2013.
26. Li, N.-S.; Lu, J.; Piccirilli, J. A. Efficient synthesis of methyl 3,5-di-O-benzyl-α- d -ribofuranoside and application to the synthesis of 2′-C-β-alkoxymethyluridines Org. Lett. 2007, 9, 3009-3012
27. Van Rompay, A. R.; Johansson, M.; Karlsson, A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases Pharmacol. Ther. 2000, 87, 189-198
28. Mehellou, Y.; Balzarini, J.; McGuigan, C. Aryloxy phosphoramidate triesters: A technology for delivering monophosphorylated nucleosides and sugars into cells ChemMedChem 2009, 4, 1779-1791
29. Klumpp, K.; Martin, J. A.; McGuigan, C.; Smith, D. B. PCT Int. Appl. WO 2007020193 A2 20070222, 2007.
30. Sofia, M. J.; Bao, D.; Chang, W.; Du, J.; Nagarathnam, D.; Rachakonda, S.; Ganapati Reddy, P.; Ross, B. S.; Wang, P.; Zhang, H.; Bansal, S.; Espiritu, C.; Keilman, M.; Lam, A. M.; Micolochick Steurer, H. M.; Niu, C.; Otto, M. J.; Furman, P. A. Discovery of a β- d -2′-deoxy-2′α-fluoro- 2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus J. Med. Chem. 2010, 53, 7202-7218
31. Lackey, D. B.; Groziak, M. P.; Sergeeva, M.; Beryt, M.; Boyer, C.; Stroud, R. M.; Sayre, P.; Park, J. W.; Johnston, P.; Slamon, D.; Shepard, H. M.; Pegram, M. Enzyme-catalyzed therapeutic agent (ECTA) design: Activation of the antitumor ECTA compound NB1011 by thymidylate synthase Biochem. Pharmacol. 2001, 61, 179-189
32. Vernachio, J. H.; Bleiman, B.; Dawn Bryant, K.; Chamberlain, S.; Hunley, D.; Hutchins, J.; Ames, B.; Gorovits, E.; Ganguly, B.; Hall, A.; Kolykhalov, A.; Liu, Y.; Muhammad, J.; Raja, N.; Robin Walters, C.; Wang, J.; Williams, K.; Patti, J. M.; Henson, G.; Madela, K.; Aljarah, M.; Gilles, A.; McGuigan, C. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties Antimicrob. Agents Chemother. 2011, 55, 1843-1851
33. Cho, A.; Zhang, L.; Xu, J.; Lee, R.; Butler, T.; Metobo, S.; Aktoudianakis, V.; Lew, W.; Ye, H.; Clarke, M.; Doerffler, E.; Byun, D.; Wang, T.; Babusis, D.; Carey, A. C.; German, P.; Sauer, D.; Zhong, W.; Rossi, S.; Fenaux, M.; McHutchison, J. G.; Perry, J.; Feng, J.; Ray, A. S.; Kim, C. U. Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. J. Med. Chem. [Online early access] DOI: 10.1021/jm400201a. Published Online: April 2, 2013.
34. Ali, S.; Leveque, V.; Le Pogam, S.; Ma, H.; Philipp, F.; Inocencio, N.; Smith, M.; Alker, A.; Kang, H.; Najera, I.; Klumpp, K.; Symons, J.; Cammack, N.; Jiang, W.-R. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479 Antimicrob Agents Chemother. 2008, 52, 4356-4369
35. Chung, S. J.; Fromme, J. C.; Verdine, G. L. Structure of human cytidine deaminase bound to a potent inhibitor J. Med. Chem. 2005, 48, 658-660
36. Perrone, P.; Luoni, G. M.; Kelleher, M. R.; Daverio, F.; Angell, A.; Mulready, S.; Congiatu, C.; Rajyaguru, S.; Martin, J. A.; Leveîque, V.; Le Pogam, S.; Najera, I.; Klumpp, K.; Smith, D. B.; McGuigan, C. Application of the phosphoramidate ProTide approach to 4′-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside J. Med. Chem. 2007, 50, 1840-1849